Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: An updated meta-analysis and review

Authors: Ping Zhan, Qin Wang, Qian Qian, Shu-Zhen Wei, Li-Ke Yu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

Many studies have examined the association between the CYP1A1 MspI and exon 7 gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent.

Methods

To assess this relationship more precisely, a meta-analysis and review were performed. The PubMed, Embase, Web of Science, and CNKI database was searched for case-control studies published up to June 2010. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.

Results

Ultimately, 64 studies, comprising 18,397 subjects from 49 case-control studies of the MspI genotype and 18,518 patients from 40 case-control studies of the exon 7 genotype, were included. A significantly elevated lung cancer risk was associated with 2 MspI genotype variants (for type C vs Type A: OR = 1.26, 95% CI = 1.12-1.42; for types B and C combined vs Type A: OR = 1.20, 95% CI = 1.13-1.28) in overall population. In the stratified analysis, a significant association was found in Asians, Caucasians, lung SCC, lung AC and Male population, not in mixed population, lung SCLC and Female population. However, inconsistent results were observed for CYP1A1 exon7 in our meta-analysis, two variants of the exon 7 polymorphism were associated with a significantly higher risk for lung cancer (for Val/Val vs Ile/Ile: OR = 1.24, 95% CI = 1.09-1.42; for (Ile/Val +Val/Val) vs Ile/Ile: OR = 1.15, 95% CI = 1.07-1.24) in overall population. In the stratified analysis, a significant assocation was found in Asians, Caucasians, lung SCC and Female population, not in mixed population, lung AD, lung SCLC and Male population. Additionally, a significant association was found in smoker population and not found in non-smoker populations for CYP1A1 MspI and exon7 gene.

Conclusions

This meta-analysis suggests that the MspI and exon 7 polymorphisms of CYP1A1 correlate with increased lung cancer susceptibility and there is an interaction between two genotypes of CYP1A1 polymorphism and smoking, but these associations vary in different ethnic populations, histological types of lung caner and gender of case and control population.
Appendix
Available only for authorised users
Literature
1.
2.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008, 83: 584-594.PubMedCentralCrossRefPubMed
3.
Alberg AJ, Brock MV, Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005, 23: 3175-85.CrossRefPubMed
4.
Rodriguez V, Tardon A, Kogevinas M, Prieto CS, Cueto A, Garcia M, Menendez IA, Zaplana J: Lung cancer risk in iron and steel foundry workers: a nested case control study in Asturias, Spain. Am J Ind Med. 2000, 38: 644-50.CrossRefPubMed
5.
Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci M, Albanes D, Hoover R, Blair A: Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control. 2005, 16: 389-97.PubMedCentralCrossRefPubMed
6.
Guengerich FP, Shimada T: Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res. 1998, 400: 201-213.CrossRefPubMed
7.
Butler JP, Post GB, Lioy PJ, Waldman JM, Greenberg A: Assessment of carcinogenic risk from personal exposure to benzo[a]pyrene in the total human environmental exposure study(THEES). J Air Waste Manag Assoc. 1993, 43: 970-977.CrossRef
8.
Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996, 56: 72-76.PubMed
9.
Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS. 1990, 1: 131-133.CrossRef
10.
Houlston RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics. 2000, 10 (2): 105-14.CrossRefPubMed
11.
Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stücker I: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control. 2003, 14 (4): 339-46.CrossRefPubMed
12.
Shi X, Zhou S, Wang Z, Zhou Z, Wang Z: CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer. 2008, 59 (2): 155-63.CrossRefPubMed
13.
Cochran WG: The combination of estimates from different experiments. Biometrics. 1954, 10: 101-29.CrossRef
14.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22: 719-48.PubMed
15.
16.
Tobias A: Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999, 8: 15-7.
17.
18.
Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL: Human CYP1A1 (cytochrome P450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991, 1: 20-25.CrossRefPubMed
19.
Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H: Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992, 1: 485-9.32.PubMed
20.
Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, Hoover RN, Weston A, Harris CC: Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev. 1993, 2 (5): 481-5.PubMed
21.
Nakachi K, Imai K, Hayashi S, Kawajiri K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993, 53: 2994-9.PubMed
22.
Alexandrie AK, Sundberg MI, Seidegård J, Tornling G, Rannug A: Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994, 15: 1785-90.CrossRefPubMed
23.
Kelsey KT, Wiencke JK, Spitz MR: A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis. 1994, 15: 1121-4.CrossRefPubMed
24.
Kihara M, Kihara M, Noda K: Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis. 1995, 16: 2331-6.CrossRefPubMed
25.
Cantlay AM, Lamb D, Gillooly M, Norrman J, Morrison D, Smith CA, Harrison DJ: Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. Clin Mol Pathol. 1995, 48: M210-M214.PubMedCentralCrossRefPubMed
26.
Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC: Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996, 5: 687-92.PubMed
27.
Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT: Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican and African-Americans. Cancer Epidemiol Biomarkers Prev. 1997, 6: 1075-80.PubMed
28.
Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC: A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes Control. 1997, 8 (4): 544-53.CrossRefPubMed
29.
Hong YS, Chang JH, Kwon OJ, Ham YA, Choi JH: Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients. Exp Mol Med. 1998, 30: 192-8.CrossRefPubMed
30.
Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K, Ohkawa A, Baba S, Morris BJ, Tsugane S, Ohno Y, Gao C, Li Z, Takezaki T, Tajima K, Iwamasa T: Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev. 1998, 7: 413-7.PubMed
31.
Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S: Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis. 1998, 19: 813-7.CrossRefPubMed
32.
Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lau AF: Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 1998, 58: 4858-63.PubMed
33.
Xue KX, Xu Lin, Chen S: Polymorphisms of the CYP1A1 and GSTM1 genes and lung cancer risk in chinese population [in Chinese]. Carcinogenesis Teratogenesis and Mutagenesis. 1999, 11: 228-230.
34.
Hu YL, Zhang Qi: Genetic Polymorphisms of CYP1A1 and Susceptibility of Lung Cancer [in Chinese]. Chin J Med Genet. 1999, 16: 26-28.
35.
Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML: Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 2000, 30: 153-60.CrossRefPubMed
36.
London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu MC: CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2000, 9: 987-91.PubMed
37.
Xue KX, Xu Lin, Chen S, Ma GJ, Wu JZ: Polymorphisms of the CYP1A1 and GSTM1 genes and their combined effects on individual susceptibility to lung cancer in a chinese pupulation[in Chinese]. Chin J Med Genet. 2001, 18: 125-127.
38.
Ratnasinghe D, Tangrea JA, Stewart C, Bhat NK, Virtamo J, Albanes D, Taylor PR: Influence of antioxidants and the CYP1A1 isoleucine to valine polymorphism on the smoking--lung cancer association. Anticancer Res. 2001, 21: 1295-9.PubMed
39.
Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, Lee K, Acevedo C, Martínez L, Aguilera AM, Gil L: CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 2001, 174: 35-44.CrossRefPubMed
40.
Song N, Tan W, Xing D, Lin D: CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001, 22: 11-6.CrossRefPubMed
41.
Chen S, Xue K, Xu L, Ma G, Wu J: Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res. 2001, 458: 41-47.PubMed
42.
Zhou X, Shi Y, Zhou Y: The Relationship betweenCYP1A1Genetic Polymorphism and Susceptibility to Lung Cancer [in Chinese]. Chin J Environ Occup Med. 2002, 19: 355-367.
43.
Yin LH, Pu YP, Lin PP: NQO1, CYP1A1, mEH genotype polymorphisms and susceptibility to lung cancer in Nanjing population [in Chinese]. Tumor. 2002, 22: 14-16.
44.
Cai XL, Chen D, Wang BG: Genetic polymorphisms of CYPIAI MsPI and susceptibility of lung Cancer in Guangdong Population[in Chinese]. Jiangsu Prev Med. 2003, 14: 1-3.
45.
Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer. 2003, 107: 139-44.CrossRefPubMed
46.
Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D: Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol. 2003, 32: 60-3.CrossRefPubMed
47.
Wang J, Deng Y, Li L: Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocar- cinoma: a case-control study in Chinese population. Cancer Sci. 2003, 94: 448-452.CrossRefPubMed
48.
Dialyna IA, Miyakis S, Georgatou N, Spandidos DA: Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep. 2003, 10: 1829-1835.PubMed
49.
Dong CT, Yang Q, Wang MZ, Dong QN: A study on the relationship between polymorphism of CYP1A1, Lack of GSTM1 and susceptibility to lung cancer [in Chinese]. J Environ Occup Med. 2004, 21: 440-442.
50.
Gu YF, Zhang SC, Lai BT, Wang H, Zhan XP: Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility [in Chinese]. Chin J Lung Cancer. 2004, 7: 112-117.
51.
Liang GY, Pu YP, Yin LH: Studies of the Genes Related to Lung Cancer Susceptibility in Nanjing Han Population, China [in Chinese]. HEREDITAS. 2004, 26: 584-588.PubMed
52.
Chen SD, Ye WY, Chen Q: Relationship between CYP1A1polymorphism, serum selenium and lung cancer[in Chinese]. Chin J Public Health. 2004, 20: 796-197.
53.
Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A: Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. Mol Cell Biochem. 2004, 266: 1-9.CrossRefPubMed
54.
Yang XR, Wacholder S, Xu Z, Dean M, Clark V, Gold B, Brown LM, Stone BJ, Fraumeni JF, Caporaso NE: CYP1A1 and GSTM1 polymorphisms in relation to lung cancer risk in Chinese women. Cancer Lett. 2004, 214: 197-204.CrossRefPubMed
55.
Wrensch MR, Miike R, Sison JD, Kelsey KT, Liu M, McMillan A, Quesenberry C, Wiencke JK: CYP1A1 variants and smoking-related lung cancer in San Francisco Bay area Latinos and African Americans. Int J Cancer. 2005, 113: 141-7.CrossRefPubMed
56.
Ng DP, Tan KW, Zhao B, Seow A: CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes Control. 2005, 16: 399-405.CrossRefPubMed
57.
Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM: Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. Cancer Causes Control. 2005, 16: 579-85.CrossRefPubMed
58.
Raimondi S, Boffetta P, Anttila S, Bröckmoller J, Butkiewicz D, Cascorbi I: Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res. 2005, 592: 45-57.CrossRefPubMed
59.
Sreeja L, Syamala V, Hariharan S, Madhavan J, Devan SC, Ankathil R: Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet. 2005, 50: 618-27.CrossRefPubMed
60.
Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG: CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis. 2005, 26: 2207-12.CrossRefPubMed
61.
Adonis M, Martı'nez V, Marı'n P, Gil L: CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica. 2005, 35: 519-530.CrossRefPubMed
62.
LI DR, Zhou QH, Guo ZL: Relationship between genetic polymorphism of CYP1A1 and lung cancer genetic susceptibility [in Chinese]. Chin J Cancer Prev Treat. 2006, 13: 1765-1768.
63.
Pisani P, Srivatanakul P, Randerson-Moor J, Vipasrinimit S, Lalitwongsa S, Unpunyo P, Bashir S, Bishop DT: GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural Thailand. Cancer Epidemiol Biomarkers Prev. 2006, 15: 667-74.CrossRefPubMed
64.
Belogubova EV, Ulibina YM, Suvorova IK: Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects. J Cancer Res Clin Oncol. 2006, 132: 327-331.CrossRefPubMed
65.
Jin Y, Yu Z: The effects of CYP1A1 gene polymorphism and p16 gene methylation on the risk of lung cancer [in Chinese]. Acta of Anhui medical University. 2007, 42: 62-66.
66.
Qi XS, Xia Y, Sun QF, Shang B: Association between genetic Polymorphisms ofCYP1A1and Lung Cancer Susceptibility for People Living in High Radon-exposed Area [in Chinese]. Carcinogenesis Teratogenesis and Mutagenesis. 2007, 20: 11-14.
67.
Yang M, Choi Y, Hwangbo B, Lee JS: Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007, 57: 135-42.CrossRefPubMed
68.
Cote ML, Wenzlaff AS, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG: Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Lung Cancer. 2007, 55: 255-62.CrossRefPubMed
69.
Xia Y, Sun QF, Shang B: Polymorphisms of the cytochrome P450 and ghtathion s-transferase genes associated with lung cancer susceptibility for the residents in high radon-exposed area [in Chinese]. Chin J Radiol Med Prot. 2008, 28: 327-332.CrossRef
70.
Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS: CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer. 2008, 60: 40-6.CrossRefPubMed
71.
Gallegos-Arreola MP, Figuera-Villanueva LE, Troyo-Sanroman R, Morgán-Villela G, Puebla-Pérez AM, Flores-Marquez MR, Zúniga-González GM: CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients. Int J Biol Markers. 2008, 23: 24-30.PubMed
72.
Shah PP, Singh AP, Singh M, Mathur N, Pant MC, Mishra BN, Parmar D: Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer. Mutat Res. 2008, 639: 1-10.CrossRefPubMed
73.
Kumar M, Agarwal SK, Goel SK: Lung cancer risk in north Indian population: role of genetic polymorphisms and smoking. Mol Cell Biochem. 2009, 322: 73-9.CrossRefPubMed
74.
Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer SK, Claeys GB, Van Dyke AL, Land SJ, Schwartz AG: Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009, 30: 626-635.PubMedCentralCrossRefPubMed
75.
Honma HN, De Capitani EM, Barbeiro Ade S, Costa DB, Morcillo A, Zambon L: Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population. J Bras Pneumol. 2009, 35: 767-772.CrossRefPubMed
76.
Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R: Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet. 2009, 195: 143-149.CrossRefPubMed
77.
Timofeeva MN, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, Jäger B, Mittelstrass K, Dienemann H, Bartsch H, Bickeböller H, Chang-Claude JC, Risch A, Wichmann HE: CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis. 2009, 30: 1161-1169.CrossRefPubMed
78.
Shaffi SM, Shah MA, Bhat IA, Koul P, Ahmad SN, Siddiqi MA: CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev. 2009, 10: 651-656.PubMed
79.
Jin Y, Xu H, Zhang C, Kong Y, Hou Y, Xu Y, Xue S: Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer:a hospital-based case-control study in China. BMC Cancer. 2010, 10: 422-PubMedCentralCrossRefPubMed
80.
Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, Yang IA, Bowman RV, Fong KM: Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J. 2010, 35: 152-159.CrossRefPubMed
81.
Hirschhorn JN, Lohmueller K, Byrne E: A comprehensive reviewof genetic association studies. Genet Med. 2002, 4: 45-61.CrossRefPubMed
82.
Sato S, Nakamura Y, Tsuchiya E: Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1994, 54: 5652-5.PubMed
83.
Wydner EL, Hoffman D: Smoking and lung cancer: scientific challenges and opportunities. Cancer Res. 1994, 54: 5284-95.
84.
Engeland A, Andersen A, Haldorsen T, Tretli S: Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control. 1996, 7: 497-506.CrossRefPubMed
85.
Zang EA, Wynder EL: Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996, 88 (3-4): 183-192.CrossRefPubMed
86.
Prescott E, Osler M, Hein HO, Borch-Johnsen K, Lange P, Schnohr P, Vestbo J: Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies. Epidemiology. 1998, 9 (1): 79-83.PubMed
87.
Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A: Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res. 1999, 59 (14): 3317-3320.PubMed
88.
Siegfried JM: Women and lung cancer: does oestrogen play a role?. Lancet Oncol. 2001, 2 (8): 506-513.CrossRefPubMed
89.
Chen Z, Li Z, Niu X, Ye X, Yu Y, Lu S, Chen Z: The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis. 2011, 26: 437-46.CrossRefPubMed
Metadata
Title
CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: An updated meta-analysis and review
Authors
Ping Zhan
Qin Wang
Qian Qian
Shu-Zhen Wei
Li-Ke Yu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-99

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Research

Application of Benchtop-magnetic resonance imaging in a nude mouse tumor model

Research

Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells

Retraction Note

Retraction Note: The candidate tumor suppressor gene ECRG4 inhibits cancer cells migration and invasion in esophageal carcinoma

Review

Platinum resistance in breast and ovarian cancer cell lines

Review

The mechanisms by which polyamines accelerate tumor spread

Research

An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits